Home > Boards > US Listed > Medical - Equipment > Cytosorbents Corporation (CTSO)

Cytosorb use to slow the aging process and

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (2) | Next 10 | Previous | Next
techxen Member Profile
 
Followed By 9
Posts 458
Boards Moderated 1
Alias Born 08/03/13
160x600 placeholder
Current Report Filing (8-k) Edgar (US Regulatory) - 6/11/2020 4:31:11 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 6/4/2020 6:02:26 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 5/12/2020 4:31:06 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 5/7/2020 6:02:00 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 5/7/2020 6:01:09 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 5/5/2020 5:06:39 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 5/5/2020 4:18:26 PM
Initial Statement of Beneficial Ownership (3) Edgar (US Regulatory) - 5/5/2020 4:17:07 PM
Quarterly Report (10-q) Edgar (US Regulatory) - 5/5/2020 4:15:20 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 5/4/2020 5:28:37 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 4/30/2020 4:17:03 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 4/30/2020 4:16:52 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 4/29/2020 4:17:22 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 4/27/2020 5:06:29 PM
Additional Proxy Soliciting Materials (definitive) (defa14a) Edgar (US Regulatory) - 4/21/2020 6:09:29 AM
Proxy Statement (definitive) (def 14a) Edgar (US Regulatory) - 4/20/2020 5:29:15 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 4/20/2020 5:19:21 PM
Prospectus Filed Pursuant to Rule 424(b)(5) (424b5) Edgar (US Regulatory) - 4/20/2020 5:17:14 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 4/20/2020 5:14:55 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 4/17/2020 7:31:08 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 4/16/2020 5:26:19 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 3/5/2020 5:19:42 PM
Annual Report (10-k) Edgar (US Regulatory) - 3/5/2020 4:13:31 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 3/3/2020 5:03:15 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 3/3/2020 5:02:54 PM
techxen   Tuesday, 06/30/20 10:52:48 AM
Re: None
Post # of 23695 
Cytosorb use to slow the aging process and progression of degenerative diseases?

The company just had a new patent published this month, for removing advanced glycation end products (AEG's) from a bodily fluids.

REDUCTION OF ADVANCED GLYCATION ENDPRODUCTS FROM BODILY FLUIDS
http://www.freepatentsonline.com/y2020/0188427.html

There is a lot to adsorb in this patent (no pun intended), but I will try and highlight a few things that stood out to me:

--------------------------------------------------------------

- Advanced glycation end products (AGEs) are proteins or lipids that become glycated as a result of exposure to sugars in the body. They are a bio-marker implicated in aging and the development, or worsening, of many degenerative diseases.

- These degenerative diseases as well as aging are mainly based on a life-long accumulation of molecular damages within molecules, cells and tissues caused by these advanced glycation end products (AGEs).

- High levels of AGEs have been linked with the development of a variety of diseases including diabetes, heart disease, kidney failure, Alzheimer's and macular degeneration.

- There is a need for methods that treat, prevent or low the progression of diseases associated with AGEs.

- (This is where things get interesting) - One application is where blood or other bodily fluid is pumped out of the body, directly through a CytoSorbâ„¢ hemoperfusion cartridge where the beads remove AGEs, and the purified fluid is then pumped back into the body. "Other bodily fluids" include saliva, nasopharyngeal fluid, blood, plasma, serum, saliva, gastrointestinal fluid, bile, cerebrospinal fluid, pericardial, vaginal fluid, seminal fluid, prostatic fluid, peritoneal fluid, pleural fluid, urine, synovial fluid, interstitial fluid, intracellular fluid, extracellular fluid, lymph, mucus, or vitreous humor.

- The patent refers to other embodiments (implementations) which address how the sorbent may be formulated - for example, a powder, a tablet, a capsule, a solution, a slurry, an emulsion, a suppository, or in a food substance. The sorbent may be packaged in portable bottles, vials, blister packs, bags, pouches, or other container that allows for either single or multiple dosages. It also refers to other ways the sorbent can be delivered or administered besides extracorporeal - for example given orally, rectally, via a feeding tube, subcutaneous or transdermal delivery, or topical.

--------------------------------------------------------------

If you are not familiar with AGE's, read this article when you have a chance, it explains everything you want to know about AGE's in layman terms:
"AGEs DamAGE Our Bodies"
http://longevityfacts.com/ages-damage-bodies-advanced-glycation-end-products/

Medical science has yet to invent a magic pill or potion that cleans a significant portion of AGEs from the body. There are drugs and enzymes being tested for use against AGEs but it's proving quite difficult as most drugs and enzymes will attempt to block the cell receptors that AGEs utilize to cause damage in the body. Although there is a lot of research with good prospects there is still to my limited research and knowledge no adequate drugs or therapies to get rid of advanced glycation end-products.

I would ask if there are those with a scientific or medical background to read this patent when they have time and also provide additional insights, because on the surface this looks to be an entirely new product that could come out of this and an entirely new market which is just mind boggling.



Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (2) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist